| Document and Entity Information - shares | 9 Months Ended | |
| Sep. 30, 2018 | Nov. 07, 2018 | |
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | BIOXYTRAN, INC | |
| Entity Central Index Key | 1,445,815 | |
| Amendment Flag | false | |
| Trading Symbol | BIXT | |
| Current Fiscal Year End Date | --12-31 | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2018 | |
| Document Fiscal Year Focus | 2,018 | |
| Document Fiscal Period Focus | Q3 | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Ex Transition Period | false | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Common Stock, Shares Outstanding | 85,103,673 |
| Consolidated Condensed Balance Sheets (Unaudited) - USD ($) | Sep. 30, 2018 | Dec. 31, 2017 |
| Current assets: | ||
| Cash | $ 2,831 | $ 110 |
| Total current assets | 2,831 | 110 |
| Total assets | 2,831 | 110 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 45,262 | |
| Accounts payable related party | 7,347 | 1,419 |
| Total current liabilities | 52,609 | 1,419 |
| Commitments and contingencies | ||
| Stockholders' equity (deficit): | ||
| Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized; 85,103,673 issued and outstanding as of September 30, 2018, and 85,103,673 issued and outstanding as of December 31, 2017 | 85,104 | 85,104 |
| Additional paid in capital | ||
| Accumulated deficit | (134,882) | (86,413) |
| Total stockholders' equity (deficit) | (49,778) | (1,309) |
| Total liabilities and stockholders' equity (deficit) | $ 2,831 | $ 110 |
| Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Sep. 30, 2018 | Dec. 31, 2017 |
| Statement of Financial Position [Abstract] | ||
| Preferred stock, par value | $ 0.001 | $ 0.001 |
| Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
| Preferred stock, shares issued | ||
| Preferred stock, shares outstanding | ||
| Common stock, par value | $ 0.001 | $ 0.001 |
| Common stock, shares authorized | 300,000,000 | 300,000,000 |
| Common stock, shares issued | 85,103,673 | 85,103,673 |
| Common stock, shares outstanding | 85,103,673 | 85,103,673 |
| Consolidated Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended |
| Sep. 30, 2018 | Sep. 30, 2018 | |
| Operating expenses: | ||
| General and administrative | $ 47,524 | $ 48,469 |
| Total operating expenses | 47,524 | 48,469 |
| Loss from operations | (47,524) | (48,469) |
| Other (expense): | ||
| Interest expense | ||
| Net loss before provision for income taxes | (47,524) | (48,469) |
| Provision for income taxes | ||
| NET LOSS | $ (47,524) | $ (48,469) |
| Loss per common share, basic and diluted | $ 0 | $ 0 |
| Weighted average number of common shares outstanding, basic and diluted | 85,103,673 | 85,103,673 |
| Consolidated Condensed Statement of Cash Flows (Unaudited) | 9 Months Ended |
| Sep. 30, 2018USD ($) | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| Net loss | $ (48,469) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |
| Stock based compensation | |
| Changes in operating assets and liabilities: | |
| Accounts payable and accrued expenses | 45,262 |
| Accounts payable related party | 5,928 |
| Net cash provided by operating activities | 2,721 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| Net cash used for investing activities | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| Net cash provided by financing activities | |
| Net increase (decrease) in cash | 2,721 |
| Cash, beginning of period | 110 |
| Cash, end of period | 2,831 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |
| Interest paid | |
| Income taxes paid |
| Background and Organization | 9 Months Ended |
| Sep. 30, 2018 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| BACKGROUND AND ORGANIZATION | NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the “Company,” formerly U.S. Rare Earth Minerals, Inc.) is an early-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company’s initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. We believe that ours is a novel approach that will result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians. Organization, Reincorporation, and Merger with U.S. Rare Earth Minerals, Inc. Bioxytan, Inc., was organized on October 5, 2017, as a Delaware corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 preferred shares with a par value of $0.0001. On September 17, 2018, the Company announced an Agreement and Plan of Merger and Reorganization among Bioxytran, Inc., U.S. Rare Earth Minerals, Inc. (“USMN”) and Bioxy Acquisition Corp. (the “Merger”). The Merger closed on September 21, 2018 (the “Acquisition Date”). After the consummation of the Merger, the Company is a wholly-owned subsidiary of USMN, and USMN (renamed Bioxytran, Inc.) is the continuing registrant and reporting company. Each outstanding share of the Company’s common stock was converted into 5.10580 shares of USMN common stock. Immediately after the Merger, the Company’s former shareholders own a majority of the voting common stock of the combined company and control the combined company’s board of directors, and the Company’s officers are now the officers of the combined company. The Merger was accounted for as a reverse acquisition, with the Company as the accounting acquirer. The Company’s accompanying historical financial statements will replace USMN’s historical financial statements when presentation of financial statements prior to the Acquisition Date is required in future filings with the U.S. Securities and Exchange Commission (“SEC”). The operations and results of USMN are consolidated with the Company from the Acquisition Date forward. The combined company has elected to continue using December 31 as its year-end. |
| Basis of Presentation | 9 Months Ended |
| Sep. 30, 2018 | |
| Basis of Presentation [Abstract] | |
| BASIS OF PRESENTATION | NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited condensed financial statements have been prepared by Bioxytran, Inc. (the “Company”) pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018. |
| Going Concern and Management's Liquidity Plans | 9 Months Ended |
| Sep. 30, 2018 | |
| Going Concern and Management's Liquidity Plans [Abstract] | |
| GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS | NOTE 3 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of September 30, 2018, the Company had cash of $2,831 and a negative working capital of $49,778. From October 5, 2017 (date of inception) through September 30, 2018, the Company has not yet generated any revenues, and has incurred cumulative net losses of $134,882. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. From October 5, 2017 (date of inception) through September 30, 2018, the Company has not raised any cash proceeds from the issuance of debt or common stock. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of September 2019 and is pursuing alternative opportunities to funding. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. |
| Stockholders' Equity | 9 Months Ended |
| Sep. 30, 2018 | |
| Equity [Abstract] | |
| STOCKHOLDERS' EQUITY | NOTE 4 – STOCKHOLDERS’ EQUITY At a Board of Director’s Meeting on July 30, 2018, the Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital (APIC). As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock. The impact of the reverse stock split has been retroactively applied to all periods presented, and all references to common and preferred stock in the footnotes are assumed to be post-split unless otherwise indicated. Preferred stock As of July 30, 2018, and prior to the reverse stock split, there were 440,500 outstanding shares of the Company’s Preferred Stock. After the reverse stock split that was effective on August 13, 2018, the Company’s outstanding shares of preferred stock was 14,683 and the authorized preferred stock of 50,000,000 shares remained unchanged. On September 20, 2018 the total of 9,999 shares of Preferred Stock were returned to treasury as a result of a Merger, (please see 8-K statement filed on September 24, 2018 and its financial amendment 8-K/A filed on October 29, 2018, for more detailed information about the merger and asset purchase agreement). The change of control of ownership resulted in the mandatory conversion of all of the outstanding shares of the Company’s Class A 6% Cumulative Convertible Voting Preferred Stock, par value $.001 per share (“Preferred Stock”), with 5 shares of common stock, par value $.001 per share (the “Common Stock”) of the Company, being issued for each outstanding share of Preferred Stock, as well as combined accrued interest. As of September 30, 2018, no preferred shares have been designated or issued. Common stock As of July 30, 2018, and prior to the reverse stock split, there were 111,336,350 shares of Common Stock outstanding. As a result of the reverse stock split that was effective on August 13, 2018, there were approximately 3,711,204 shares of Common Stock outstanding. A total of 30,000 shares, included in the above count, had on July 30, 2018 been issued as a settlement of accounts payable for a related party. On September 21, 2018, the Company completed a series of transactions as a result of a Merger, (please see 8-K statement filed on September 24, 2018 and its financial amendment 8-K/A filed on October 29, 2018, for more detailed information about the merger and asset purchase agreement). As consideration for the Merger, the stockholders of Bioxytran were issued 76,586,937 shares of common stock of the Company. The Merger was structured as a tax-free reorganization. A 6% secured promissory note in the principal amount of $110,000, including all interest had been in default since August 23, 2013. The Note was secured by substantially all of the assets of the Company. As consideration for the satisfaction of the obligation and as a condition to the Settlement, the Company agreed to divest substantially all of its assets and remaining liabilities to an affiliate of the creditor and former majority stockholder of the Company. The creditor agreed to release all liens upon the completion of the asset sale. Included in the Settlement a former majority stockholder of the Company received 4,455,856 shares of common stock, while the former Directors and Officers received 850,732 shares of common Stock. An additional 30,500 shares of common stock were issued as a result of a mandatory conversion of 4,681 shares preferred stock, convertible 5:1 while, 7,095 shares of common stock were issued in form of accrued 6% annual combined interest on the preferred stock. An additional 9,999 shares of preferred stock were returned to treasury. As of September 30, 2018, and after completion of the above transactions, the Company has 85,103,673 shares of Common Stock issued and outstanding. |
| Commitments and Contingencies | 9 Months Ended |
| Sep. 30, 2018 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| COMMITMENTS AND CONTINGENCIES | NOTE 5 – COMMITMENTS AND CONTINGENCIES Employment contracts The Company’s executive officers have entered into employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable. During the period of these quarterly statements from December 31, 2017 to September 30, 2018, and through the issuance of these financial statements, the Company was not involved in any legal proceedings. |
| Subsequent Events | 9 Months Ended |
| Sep. 30, 2018 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | NOTE 6 – SUBSEQUENT EVENTS In preparing the financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through the date the financial statements were available to be issued. On October 3, 2018, the Company made a 14F-1 filing with the SEC, announcing that on September 21, 2018 there was a change of control of the majority ownership of the Company with the Dr. David Platt, the new Chairman, President and Chief Executive Officer, and Mr. Ola Soderquist, Chief Financial Officer, holding together approximately 77% of the issued and outstanding common stock of the Company, as well of an upcoming change of the Board of Directors. The information statement has also been posted on the Company’s web-site (http://www.bioxytraninc.com/info14f-12018/) and mailed out to the shareholders on October 15, 2018. On October 26, 2018 the Company announced through issuance of an 8-K filing that the changes of control and ownership have entered into effect. On October 3, 2018, the Company made a PRE 14C filing with the SEC, followed with a DEF 14C filing on October 15. The purpose of the filing is for the shareholders to ratify the asset sale as described under Note 1 and Note 4 as well as in the 14F-1 filing in the above. Further, the filing informs shareholders about the name change to BIOXYTRAN, INC. The information statement has also been posted on the Company’s web-site (http://www.bioxytraninc.com/info14c2018/) and mailed out to the shareholders on October 15, 2018. On November 7, 2018 the Company announced through issuance of an 8-K filing that the Company officially changed its name from U.S. Rare Earth Minerals, Inc. into Bioxytran, Inc. In connection with its name change, on November 7, 2018, Bioxytran’s shares of common stock began trading on the OTC Markets (Pink) under its new ticker symbol “BIXT,” and ceased trading under the ticker symbol “USMN.” The new CUSIP number for Bioxytran, Inc.’s shares of common stock is 09075D 102. On October 28, 2018 the Company entered into a convertible loan Agreement with Auctus Fund, LLC, a Delaware limited liability company, thereby securing a $250,000 loan for preparing the Company’s S/1 and an additional $250,000 once the S/1 is filed in order to proceed with the Company’s secondary offering, see the next paragraph here below. All details about this loan agreement have earlier been released in an 8-K, filed with the SEC on October 30, 2018. On November 2, 2018 the Company announced the retirement of the entire former Board of Directors and the election of a new Board of Directors, see item 6 under Part II - Other Information, here below for more detailed information about the new Directors. The board voted to compensate each of Dr. Platt and Mr. Soderquist in form of a monthly salary of $6,000, as of October 1, 2018, while the Company’s non-employee Directors will be compensated with 1,000 shares per board meeting as of November 2018. Further, the Board of Directors also voted on the issuance of a secondary offering, where an initial Form S-1 will be prepared and submitted to the SEC at the earliest convenient date. On November 7, 2018 the Company announced through issuance of an 8-K filing that a new Board of Directors had been elected. |
| Background and Organization (Details) - $ / shares | Sep. 21, 2018 | Sep. 30, 2018 | Dec. 31, 2017 | Oct. 05, 2017 |
| Converted into common stock, shares | 5.10580 | |||
| Common stock, par value | $ 0.001 | $ 0.001 | ||
| Common stock, shares authorized | 300,000,000 | 300,000,000 | ||
| Preferred stock, par value | $ 0.001 | $ 0.001 | ||
| Preferred stock, shares authorized | 50,000,000 | 50,000,000 | ||
| Delaware [Member] | ||||
| Common stock, par value | $ 0.0001 | |||
| Common stock, shares authorized | 95,000,000 | |||
| Preferred stock, par value | $ 0.0001 | |||
| Preferred stock, shares authorized | 5,000,000 |
| Going Concern and Management's Liquidity Plans (Details) - USD ($) | 12 Months Ended | |
| Sep. 30, 2018 | Dec. 31, 2017 | |
| Going Concern and Management's Liquidity Plans (Textual) | ||
| Cash | $ 2,831 | $ 110 |
| Negative working capital | (49,778) | |
| Cumulative net losses | $ (134,882) | $ (86,413) |
| Stockholders' Equity (Details) - USD ($) | 1 Months Ended | 9 Months Ended | ||||
| Jul. 30, 2018 | Sep. 30, 2018 | Sep. 20, 2018 | Aug. 13, 2018 | Dec. 31, 2017 | Aug. 23, 2013 | |
| Stockholders' Equity (Textual) | ||||||
| Description of reverse stock split | The Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital (APIC). As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock. | |||||
| Preferred stock, par value | $ 0.001 | $ 0.001 | ||||
| Preferred stock, shares authorized | 50,000,000 | 50,000,000 | ||||
| Preferred stock, shares issued | ||||||
| Preferred stock, shares outstanding | ||||||
| Common stock, par value | $ 0.001 | $ 0.001 | ||||
| Common stock, shares authorized | 300,000,000 | 300,000,000 | ||||
| Common stock, shares issued | 85,103,673 | 85,103,673 | ||||
| Common stock, shares outstanding | 85,103,673 | 85,103,673 | ||||
| Issued shares of common stock | 76,586,937 | |||||
| Principal amount | $ 110,000 | |||||
| Percentage of secured promissory note | 6.00% | |||||
| Additional shares of common stock were issued | 30,500 | |||||
| Conversion of shares preferred stock | 4,681 | |||||
| Convertible conversion ratio | 5:1 | |||||
| Common shares issued as cumulative interest on converted preferred shares | 7,095 | |||||
| Percentage of annual combined interest on preferred stock | 6.00% | |||||
| Additional shares of preferred stock were returned to treasury | 9,999 | |||||
| Former majority stockholder [Member] | ||||||
| Stockholders' Equity (Textual) | ||||||
| Received shares of common stock | 4,455,856 | |||||
| Former Directors and Officers [Member] | ||||||
| Stockholders' Equity (Textual) | ||||||
| Received shares of common stock | 850,732 | |||||
| Preferred Stock [Member] | ||||||
| Stockholders' Equity (Textual) | ||||||
| Preferred stock, shares outstanding | 440,500 | 14,683 | ||||
| Total shares of preferred stock were returned to treasury | 9,999 | |||||
| Common Stock [Member] | ||||||
| Stockholders' Equity (Textual) | ||||||
| Common stock, shares outstanding | 111,336,350 | 3,711,204 | ||||
| Total of shares issued as settlement of accounts payable for a related party | 30,000 | |||||
| Class "A" 6% Cumulative Convertible Voting Preferred Stock [Member] | ||||||
| Stockholders' Equity (Textual) | ||||||
| Conversion of stock, description | The change of control of ownership resulted in the mandatory conversion of all of the outstanding shares of the Company’s Class A 6% Cumulative Convertible Voting Preferred Stock, par value $.001 per share (“Preferred Stock”), with 5 shares of common stock, par value $.001 per share (the “Common Stock”) of the Company, being issued for each outstanding share of Preferred Stock, as well as combined accrued interest. |
| Subsequent Events (Details) - Subsequent Event [Member] | Nov. 02, 2018 | Oct. 28, 2018 | Oct. 03, 2018 |
| Subsequent Events (Textual) | |||
| Percentage of issued and outstanding common stock | 77.00% | ||
| Description of convertible loan agreement | The Company entered into a convertible loan Agreement with Auctus Fund, LLC, a Delaware limited liability company, thereby securing a $250,000 loan for preparing the Company’s S/1 and an additional $250,000 once the S/1 is filed in order to proceed with the Company’s secondary offering. | ||
| Description of compensation arrangements | The board voted to compensate each of Dr. Platt and Mr. Soderquist in form of a monthly salary of $6,000, as of October 1, 2018, while the Company’s non-employee Directors will be compensated with 1,000 shares per board meeting as of November 2018. |
